CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 101 enrolled
Drug / intervention
Olanzapinedrug
Likely dose
Olanzapine 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00618748
NCT00618748Phase 3Completed
CompareCT.gov

Safety and Efficacy of Olanzapine (LY170053) in the Long-term Treatment for Patients With Bipolar I Disorder, Depressed

Eli Lilly and Company·interventional·Posted Feb 20, 2008·Updated Jul 27, 2011

In Brief

A Phase 3 clinical trial evaluating Olanzapine for Bipolar I Disorder. Completed, enrolled 101 participants across 10 sites.

Detailed Summary

To assess the efficacy and safety of olanzapine in the long-term treatment for patients with bipolar I disorder, depressed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar I Disorder
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 20, 2008
Enrollment StartFeb 1, 2008
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 18.4 years ago

Interventions

Olanzapinedrug

5-20 mg/day, oral, daily